ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0910

Rheumatoid Arthritis Associated Interstitial Lung Disease: The Role of Non-Criteria Autoantibodies

Albert Pérez-Isidro1, Raul Castellanos-Moreira1, Juan Camilo Sarmiento-Monroy2, Noemi de Moner1, Maresa Grundhuber3, Odette Vinas1, Raimon Sanmarti2 and Estibaliz Ruiz-Ortiz1, 1Hospital Clinic of Barcelona, Barcelona, Spain, 2Hospital Clínic de Barcelona, Barcelona, Spain, 3Thermo Fisher Scientific, Freiburg, Germany

Meeting: ACR Convergence 2022

Keywords: Anti-ACPA, Autoantibody(ies), interstitial lung disease, rheumatoid arthritis, Rheumatoid Factor

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic joint inflammation. RA-associated interstitial lung disease (ILD) is the most frequent and severe extra-articular manifestation and is associated with an increase of mortality. Rheumatoid Factor (RF-IgM) and anti-citrullinated peptide antibodies (ACPA-IgG) are important diagnostic tools included in the classification criteria (ACR/EULAR 2010). However, new biomarkers are still needed, to diagnose and predict patient’s disease subsets and prognosis.

The aim of this study was to analyse the prevalence and the association with RA-ILD of non-criteria isotypes of RF, ACPA and anti-hnRNP-A2/B1 (RA33) in Hospital-Clínic Arthritis-Unit RA cohort.

Methods: This cross-sectional study included 229 patients with definite RA (ACR/EULAR 2010 criteria). ILD was diagnosed after clinical suspicion and confirmed by high resolution computed tomography. Serum samples from all RA patients and 50 healthy controls were tested for IgM/IgG/IgA of RF, ACPA (CCP2 antigen) and RA33 using EliA™ Platform (Thermo Fisher Scientific, Phadia AB, Sweden). Cut-off values were established with 95%-specificity for healthy controls.

Results: ILD was confirmed in 57 patients (RA-ILD). IgA isotype for ACPA (OR: 2.1 [1.1-4.0]), IgA-RF (OR: 2.8 [1.2-6.5]), as well as IgG-RF (OR: 2.8 [1.5-5.3]) were associated with ILD in RA.

Combinations of non-criteria autoantibodies showed a wide sensitivity (70.2% – 36.8%) and specificity (84.3% – 50.0%) range for ILD in RA. Particularly, IgA-ACPA + IgA-RF + IgG-RF showed 52.6% sensitivity and 74.4% specificity.

Conclusion: This study confirms the association of IgA-ACPA antibodies with RA-ILD, but no association with IgG-ACPA was observed. Moreover, both IgA-RF and IgG-RF are associated with RA-ILD. The results of the present study support the role of mucosal immunity in the development of ILD in patients with RA. Combinations of non-criteria autoantibodies could be useful to identify RA-ILD patients.

More prospective studies to confirm the non-criteria autoantibodies predictive value for RA-ILD stratification are warranted.


Disclosures: A. Pérez-Isidro, Thermo Fisher Scientific; R. Castellanos-Moreira, Thermo Fisher Scientific; J. Sarmiento-Monroy, None; N. de Moner, Thermo Fisher Scientific; M. Grundhuber, Thermo Fisher Scientific; O. Vinas, Thermo Fisher Scientific; R. Sanmarti, Thermo Fisher Scientific; E. Ruiz-Ortiz, Thermo Fisher Scientific.

To cite this abstract in AMA style:

Pérez-Isidro A, Castellanos-Moreira R, Sarmiento-Monroy J, de Moner N, Grundhuber M, Vinas O, Sanmarti R, Ruiz-Ortiz E. Rheumatoid Arthritis Associated Interstitial Lung Disease: The Role of Non-Criteria Autoantibodies [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/rheumatoid-arthritis-associated-interstitial-lung-disease-the-role-of-non-criteria-autoantibodies/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatoid-arthritis-associated-interstitial-lung-disease-the-role-of-non-criteria-autoantibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology